Welcome to our dedicated page for Liquidia Corporation SEC filings (Ticker: LQDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Liquidia Corporation (NASDAQ: LQDA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Delaware corporation focused on biopharmaceutical products for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH‑ILD), Liquidia uses these filings to report financial results, material agreements, governance changes and other significant events.
Investors can review Forms 10‑K and 10‑Q for detailed discussions of Liquidia’s business, including its PRINT® technology platform, the commercialization of YUTREPIA™ (treprostinil) inhalation powder, development of the investigational L606 treprostinil liposome inhalation suspension, and promotion of generic Treprostinil Injection under a profit‑sharing agreement with Sandoz. These periodic reports typically include segment information, research and development spending, risk factors related to PAH and PH‑ILD markets, and descriptions of key contracts.
Current reports on Form 8‑K highlight specific events such as quarterly earnings releases, financing transactions under the revenue interest financing agreement with HealthCare Royalty Partners IV, L.P. (HCR), entry into the exclusive license with Vectura for the nebulizer device used with L606, leases for expanded manufacturing facilities in Morrisville, North Carolina, and outcomes of annual stockholder meetings. Other 8‑K filings may document executive appointments, compensation arrangements and other governance matters.
Users can also monitor proxy statements and Form 4 insider transaction reports to understand board elections, advisory votes on executive compensation and equity awards to officers and directors. Stock Titan’s interface combines these documents with AI‑powered summaries that explain complex sections of long filings, highlight key changes from prior periods and help clarify how new agreements, clinical developments or financing structures may affect Liquidia’s operations and capital structure.
With real‑time updates from EDGAR and structured access to historical filings, this page serves as a central resource for analyzing Liquidia’s regulatory history, capital markets activity and disclosures related to its treprostinil‑based therapies for PAH and PH‑ILD.
Paul B. Manning, a director of Liquidia Corp (LQDA), reported multiple sales of Common Stock in late August and early September 2025. The Form 4 shows sales on 08/28/2025 (154,337 shares at a weighted average $27.94), 08/29/2025 (188,232 shares at $27.62 weighted average), and two sales on 09/02/2025 (254,038 shares at $28.67 weighted average and 74,230 shares at $29.14 weighted average). The filing lists several holdings held indirectly through trusts and entities (including PBM 2024 GRAT, PBM 2000 Trust, BKB Growth Investments, PBM Capital Finance, and PD Joint Holdings) and notes 3,131,794 shares disposed of in total on one line and various indirect ownership amounts disclosed in footnotes.
Insider transactions by Jason Adair, Chief Business Officer of Liquidia Corporation (LQDA). The Form 4 reports vesting and sales of restricted stock units (RSUs) and open-market sales made under Rule 10b5-1 plans. On 07/11/2025 Mr. Adair had 3,906 RSUs converted to common stock. Subsequent sales: 26,057 shares sold on 08/28/2025 at a VWAP of $27.8564 and 451 shares sold on 09/02/2025 at $29.05. A 1,562-share RSU conversion occurred on 08/29/2025. The filing discloses total beneficial ownership adjustments including unvested RSU balances from grants dated 01/11/2023, 07/06/2023, 01/11/2024 and 01/11/2025 and 10,746 shares from the 2020 ESPP; corrected prior filing counts are also noted.
Dr. Rajeev Saggar, Chief Medical Officer of Liquidia Corporation (LQDA), reported a sale of 20,000 shares of common stock on 08/28/2025. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on May 29, 2025 and produced a volume-weighted average price of $27.8536 (prices on the day ranged from $27.22 to $28.53). After the transaction, Dr. Saggar beneficially owned 249,727 shares, which include multiple unvested restricted stock unit (RSU) grants totaling 138,356 unvested RSUs from grants dated January 11, 2023, 2024 and 2025, plus 7,131 shares acquired under the company ESPP. The Form 4 is signed by Dr. Saggar on 09/02/2025.
Form 144 notice for Liquidia Corporation (LQDA) shows a proposed sale of 70,000 common shares through Morgan Stanley Smith Barney at an aggregate market value of $1,937,600, with an approximate sale date of 09/02/2025 on NASDAQ. The shares were acquired in three tranches: 8,315 via an Employee Stock Purchase Plan on 08/31/2022, 7,650 as Performance Stock Units on 11/10/2021, and 54,035 as Restricted Stock Units on 07/11/2024; payment where applicable was in cash or recorded as N/A. The filing lists two recent sales by the same seller, totaling 11,453 shares for gross proceeds of $181,453.48. The filer represents they are unaware of undisclosed material adverse information.
Paul Manning filed a Form 144 reporting proposed and recent sales of Liquidia Corporation (LQDA) common stock. The filing lists a proposed sale of 947,328 shares with an aggregate market value of $26,146,252.80, using Fidelity Brokerage Services (NASDAQ) with an approximate sale date of 08/29/2025. The filer disclosed prior acquisitions between 2018 and 2022 totaling reported lots of shares, and a sale on 08/28/2025 of 154,337 shares that generated $4,312,469.02 in gross proceeds. The filer certifies no undisclosed material adverse information.
Form 144 notice for Liquidia Corporation (LQDA) shows a proposed sale of 20,000 common shares through Morgan Stanley Smith Barney with an aggregate market value of $560,000 and an approximate sale date of 08/28/2025 on NASDAQ. The shares were acquired as Restricted Stock Units on 07/18/2023. The filer, Rajeev Saggar, also reported three recent sales in the past three months totaling 15,450 shares for $242,713.33 in gross proceeds on 06/04/2025, 07/14/2025, and 07/21/2025. The filing includes the required representation that the signer is not aware of undisclosed material adverse information.
Liquidia Corporation (LQDA) Form 144 notice reports a proposed sale of 26,057 common shares with an aggregate market value of $729,596.00, to be sold approximately on 08/28/2025 on NASDAQ. The filing identifies the securities were acquired as 13,425 performance stock units on 11/10/2021 and 12,632 restricted stock units on 03/18/2024, both from the issuer. It discloses prior open-market sales by the same seller in the past three months totaling 7,078 shares for $114,243.82. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information and follows Rule 144 disclosure requirements.
Liquidia Corporation (LQDA) filing a Form 144 reports a proposed sale of 154,337 common shares through Fidelity Brokerage Services with an aggregate market value of $4,312,469.02. The filing lists approximately 86,091,454 shares outstanding, and an approximate sale date of 08/28/2025. The shares to be sold were acquired on multiple dates: 392,156 shares on 04/13/2022 (secondary, cash), and earlier open-market purchases in 2018 and 2019 totaling additional shares. No securities were reported sold by the person in the past three months. The filer affirms they are not aware of undisclosed material adverse information and includes the standard Rule 144 representations.
Liquidia Corporation director Dr. Joanna Horobin reported a sale of 5,000 shares of common stock on 08/19/2025 at a price of $27.17 per share. After this disposition she beneficially owns 33,755 shares directly. The filing also discloses 18,396 restricted stock units granted to her on June 17, 2025 that have not vested as of the transaction date.
Liquidia Corporation (LQDA) notice reports a proposed sale under Rule 144 of 5,000 common shares through Morgan Stanley Smith Barney LLC on NASDAQ, with an approximate sale date of 08/19/2025 and an aggregate market value of $135,850.00. The filing states total shares outstanding of 86,091,454. The securities were acquired as Restricted Stock Units from Liquidia Corporation on 06/16/2025, representing 20,359 units in the acquisition event; payment is noted as N/A. No sales by the reporting person in the prior three months are reported. The filer affirms there is no undisclosed material adverse information about the issuer and includes a signature/representation regarding Rule 10b5-1 plan adoption if applicable.